MedeliX
Start asking

liraglutide

Ablymico, Liraglutide STADA, Saxenda, Victoza · ATC code A10BJ02

Also known as: Liraglutid · Brand names: Ablymico, Liraglutide STADA, Saxenda, Victoza, Ejulir, Lirabelin, Liraglutid Reddy, Liraglutid Zentiva, Luntin, Obexorin, Zegluxen, Zinnentis, Byesilor, Diavic, Ladiazyl …

Key facts
Active substance
liraglutide
Drug class
Glucagon-like peptide-1
ATC code
A10BJ02
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Ablymico 6 mg/mL solution for injection in pre-filled pen · Liraglutide STADA 6 mg/ml solution for injection in pre-filled pen · Saxenda 6 mg/ml solution for injection in pre-filled pen · Victoza 6 mg/ml solution for injection in pre-filled pen
Marketing authorisation holder
STADA Arzneimittel AG, Novo Nordisk A/S
Information as of
2026-10-27

Key facts

Liraglutide is a GLP-1 receptor agonist used for type 2 diabetes (Victoza, Liraglutide STADA) and for weight management in obesity or overweight (Saxenda, Ablymico).

What it is used for

  • Victoza/Liraglutide STADA: insufficiently controlled type 2 diabetes in adults, adolescents and children aged 10 years and above, alone or with other antidiabetics
  • Saxenda/Ablymico: weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with a weight-related comorbidity
  • Saxenda/Ablymico: adolescents aged 12 years and above with obesity and body weight above 60 kg
  • As an adjunct to diet and physical activity

Dosing

  • Victoza/Liraglutide STADA (diabetes): start 0.6 mg daily, after at least one week 1.2 mg, possibly 1.8 mg; above 1.8 mg daily not recommended.
  • Saxenda/Ablymico (weight): start 0.6 mg once daily, increase by 0.6 mg weekly to 3.0 mg; above 3.0 mg not recommended.
  • Saxenda/Ablymico: stop after 12 weeks on 3.0 mg/day if at least 5% of body weight has not been lost (adolescents: 4% of BMI).
  • With a sulfonylurea or insulin: reduce their dose to lower hypoglycaemia risk.
  • Once daily subcutaneously (abdomen, thigh, upper arm), independent of meals; not intravenously or intramuscularly.

Contraindications

  • Hypersensitivity to the active substance or any excipient

Important warnings

  • Acute pancreatitis; discontinue if suspected
  • Aspiration risk with general anaesthesia or deep sedation due to delayed gastric emptying
  • Not for type 1 diabetes or diabetic ketoacidosis; not a substitute for insulin
  • Not recommended in NYHA class IV heart failure, inflammatory bowel disease and diabetic gastroparesis
  • Saxenda/Ablymico: not recommended in severe renal or hepatic impairment or from 75 years

Side effects

  • Most frequent are gastrointestinal: nausea, diarrhoea, vomiting, constipation
  • Also abdominal pain, dyspepsia, headache, dizziness; hypoglycaemia (very common with a sulfonylurea)
  • Weight management: gastrointestinal reactions overall in 67.9%
  • Uncommon to rare: pancreatitis, dehydration, tachycardia, intestinal obstruction

Interactions

  • Delayed gastric emptying may affect absorption of oral medicines; no dose adjustment required
  • Warfarin and other coumarins: more frequent INR monitoring at the start
  • Do not combine with another GLP-1 receptor agonist

Pregnancy and breastfeeding

  • Should not be used in pregnancy; stop if pregnancy is planned or occurs (insulin is recommended in diabetes).
  • Should not be used during breast-feeding.

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Austria

  • EjulirViatris Limited · 1 register entry
  • LirabelinGenericon Pharma Gesellschaft M.B.H. · 1 register entry
  • Liraglutid ReddyReddy Holding Gmbh · 1 register entry
  • Liraglutid ZentivaZentiva, K.S. · 1 register entry
  • LuntinZentiva, K.S. · 1 register entry
  • ObexorinBiocon Pharma Malta I Limited · 1 register entry
  • ZegluxenZentiva, K.S. · 1 register entry
  • ZinnentisExeltis Germany Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Germany

  • ByesilorBasics Gmbh · 1 register entry
  • DiavicBasics Gmbh · 1 register entry
  • LadiazylBiocon Pharma Malta I Limited · 1 register entry
  • Liraglutid AlAliud Pharma Gmbh · 1 register entry
  • Liraglutid BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Liraglutid CiplaCipla Europe Nv · 1 register entry
  • Liraglutid ViatrisViatris Germany Gmbh · 1 register entry
  • Liraglutid ZentivaZentiva Pharma Gmbh · 1 register entry
  • Liraglutide AdalvoAdalvo Limited · 1 register entry
  • LiramedCipla Europe Nv · 1 register entry
  • LobezylBiocon Pharma Malta I Limited · 1 register entry
  • NevolatZentiva Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • SaxendaNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 3 register entries
  • VictozaNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 5 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 24 more European countries
Belgium
Byesilor, Zinnentis
Bulgaria
Зеглуксен
Croatia
Zegluxen
Czechia
Ejulir, Plyzari, Sudaclin, Zegluxen
Denmark
Ejulir, Liraglutid "biogaran", Liraglutid Teva Gmbh, Liraglutid Zentiva, Liraglutide Medical Valley, Siluxir
Estonia
Liraglutide Zentiva, Siluxir
Finland
Diavic, Metlyra, Triglyva, Zinnentis
France
Liendax, Liraglutide Biogaran, Liraglutide Cipla, Liraglutide Reddy Pharma, Liraglutide Sun, Liraglutide Viatris, Liraglutide Zentiva
Hungary
Liendax
Iceland
Ablymico, Liraglutide Stada, Saxenda, Siluxir, Victoza
Ireland
Ejulir
Italy
Byesilor, Diavic, Liraglutide Dr. Reddy’s, Liraglutide Eg, Liraglutide Mylan, Liraglutide Zentiva, Liratight, Plyzari
Latvia
Liraglutide Zentiva, Siluxir
Liechtenstein
Ablymico, Liraglutide Stada
Lithuania
Liraglutide Zentiva
Luxembourg
Zinnentis
Netherlands
Byesilor, Diavic, Ejulir, Liraglutide Xiromed, Liraglutide Zentiva, Nevolat, Siluxir
Norway
Ablymico, Liraglutid Zentiva, Liraglutide Medical Valley, Liraglutide Stada, Liramed, Nevolat, Saxenda, Siluxir, Triglyva, Victoza
Poland
Byesilor, Diavic, Ejulir, Plyzari, Polidia, Triglyva, Zegluxen
Portugal
Liraglutido Farmoz, Liraglutido Pentafarma, Liraglutido Zentiva, Lyact, Nolimerin, Plyzari, Zinnentis
Romania
Byesilor, Diavic, Ejulir, Liraglutid Cipla, Liraglutid Dr. Reddy’s, Zegluxen
Slovakia
Sudaclin
Spain
Byesilor, Diavic, Diavorin, Ejulir, Liraglutida Cinfa, Liraglutida Dr. Reddys, Liraglutida Tecnigen, Liraglutida Tecnimede, Liraglutida Zentiva, Liramed, Liratight, Mirbeltra, Nolimerin, Obexorin, Plyzari
Sweden
Aglira, Diavic, Ejulir, Liraglutid Pentafarma, Liraglutid Sun Pharma, Liraglutid Tecnigen, Liraglutid Zentiva, Liraglutide Medical Valley, Liraglutide Reddy, Liraglutide Stada Arzneimittel Ag, Liramed, Nevolat, Nolimerin, Polidia, Siluxir, Triglyva

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Ablymico – EPAR, Product Information (OF THE TEXT {MM/YYYY}). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/ablymico-epar-product-information_en.pdf
  2. European Medicines Agency. Liraglutide STADA – EPAR, Product Information (OF THE TEXT {MM/YYYY}). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/liraglutide-stada-epar-product-information_en.pdf
  3. European Medicines Agency. Saxenda – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf
  4. European Medicines Agency. Victoza – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_en.pdf
  5. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  6. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  7. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  8. Wikidata (CC0): ATC A10BJ.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.